Partner, European Patent Attorney
Robert handles patent work in our chemistry & materials team with particular experience in the pharmaceutical, industrial chemistry, nanotech and agricultural sciences sectors. He is also a leading member of our designs team.
His extensive experience in the pharmaceutical sector includes working with clients engaged in drug discovery and development. He has advised on the protection of two drugs from initial discovery, one of which is in Phase II, the other which is approved in both the US and EU, and on strategies to further protect these commercial drugs. Robert also has experience with patents relating to polymorphic forms of drugs, and in assisting his pharmaceutical clients in negotiating agreements and undergoing due diligence.
In the agricultural science sector, his work focuses on agrochemicals and his industrial chemistry sector experience includes polymers. He also works in the nanotech sector on novel nanoscale materials, and novel methods of producing graphene.
He deals mainly with drafting and prosecution and advises on global portfolio management and invention capture. Robert assists clients in licensing of IP.
Robert was ‘Recommended’ in the IAM Patent 1000 for prosecution 2014 guide which noted “Robert Watson; first-rate global portfolio management work has won him admirers on all continents”. He is a also ‘Recommended’ in 2015 guide which noted “Robert Watson files patents that stand the test of time and he never fails to deliver anything less than valuable assets.” Robert is again ‘Recommended’ in the 2016 guide for “advising KuDOS Pharmaceuticals, an AstraZeneca company, on its patent portfolio relating to Lynparza – an anti-cancer drug that was recently approved in the United States and Europe for BRCA mutated advanced ovarian cancer.” Robert is again recognised for being “able to effectively communicate with scientists, quickly understand technologies and devise plans for effectively protecting any new ideas” in the IAM Patent 1000, 2017. His work to ‘forge bulletproof strategies’ to defend KuDOS Pharmaceuticals’ Lynparza anti-cancer drug was highlighted again.
Robert was individually recognised in Managing Intellectual Property’s IP Stars 2014 -2016 as an ‘IP Star’. Robert was once again named a ‘Patent Star’ in the 2018 edition of IP Stars.
Legal 500 2016 researchers note “Robert Watson impresses clients with his ‘overall quality of client service and in-depth knowledge of the pharmaceutical domain’.” Robert is also recommended in the 2017 edition of The Legal 500.
Robert has also been recognised as an Acritas Star independently rated lawyer in 2018. Upon nominating Robert as a stand-out lawyer, Robert’s clients commented that what makes him stand-out is ‘his technical expertise, the quality of his advice, and successful representation in European opposition proceedings.’
His clients include British universities, charities, spin out companies, SMEs and multi-nationals.
Robert was President of FICPI-UK from 2011 to 2015 and is currently Vice-President of FICPI’s Work and Study Commission (CET) and Europe Members Commission (EUCOF) in which capacities he meets the European Commission, EPO, EUIPO, WIPO and other patent offices. He is a member of the Designs and Copyright committee of CIPA. He regularly speaks at conferences about European design law.
Robert has a degree in chemistry from Oxford University which included study and research in quantum chemistry.
Robert joined Mewburn Ellis LLP in 1995, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 1999. He is a Representative authorised to act before EUIPO. Robert joined the partnership in 2001.